Diabetic Nephropathy Market Research Report - Forecast to 2027

Diabetic Nephropathy Market Information: By Diagnosis (Urine Test, Blood Test), By Treatment (Medications, Kidney Dialysis, Transplant), By Indication (Diabetes 1, Diabetes 2), By End User (Hospital & Clinic, Surgical Centers) - Forecast Till 2027

ID: MRFR/Pharma/4209-HCR | | Region: Global | 110 pages

Diabetic Nephropathy Market Overview 


Diabetic Nephropathy Market is expected to grow at a CAGR of 5.2% during the forecast period.


Diabetic Nephropathy is a condition that comes as a side effect for diabetic patients. The damaged blood vessels cause the condition which leads to damage to the kidney and makes them futile in the long run if the condition is not monitored or managed well. Over 50% of diabetic patients with 20 years of disease duration are more likely to possess Diabetic Nephropathy. Chronic illness affects the functioning of the kidneys and leads to kidney failures or even life-threatening conditions. The increasing diabetic cases across the globe have increased the demand for services related to the Diabetic Nephropathy market in recent years. 


Diabetic Nephropathy requires preventive care measures such as proper monitoring of blood pressure and a healthy lifestyle and diet to manage the condition. Early diagnosis and treatment offer higher chances of reducing the severity of the condition. There are minimal or no symptoms found at the early stages of the condition. However, swelling of the leg, nocturia, nausea, vomiting, and high BP are the common signs found in the advanced stages of Diabetic Nephropathy.  


COVID 19 Analysis: 


The Diabetic Nephropathy condition was increasing in the countries like the United States since the isolation imposed due to the pandemic has increased the severity of diabetic patients. As the grocery stores were closed or people remained home have started consuming unhealthy diet, especially not suitable for people with Diabetic Nephropathy condition. A study states that more than 40% of people who died of COVID had diabetes. The inaccessibility of healthy food options and places like gyms or jogging tracks has worsened the condition. 


The disruption in the supply chain and reduction in the production units have limited the raw materials required to manufacture the diabetes monitoring devices. This factor has also impacted the Diabetic Nephropathy industry during the pandemic. 


Market dynamics: 


Market drivers: 


The increasing chronic diseases such as obesity, diabetes, and other chronic illness have increased the demand for diagnostic tests like urine tests, blood tests, tests related to kidney functioning, and imaging tests like MRI and CT scans. The mortality rate has increased to 59% and the number of deaths has increased to 35 million in the year 2019. These factors are driving the Diabetic Nephropathy market growth in recent years.  


The recent treatments of administrating drugs like Spironolactone followed by Eplerenone for the patients with mild or moderate arterial hypertension and albuminuria. The recent approval for novel drugs like finerenone has a significant impact on the glomerular filtration rate. Such factors have promoted the growth of the Diabetic Nephropathy industry. 


Market opportunities: 


The surging success rates in disease-modifying therapies that include the drugs like Angiotensin II receptor blockers and Angiotensin-converting enzyme inhibitors have created a huge impact on the growth of the Diabetic Nephropathy market value. Additionally, the superior protection offered by the ACE inhibitors and ARB inhibitors has increased the life of the failing kidneys of the patients when administrated. Such factors have increased the demand for the Diabetic Nephropathy industry. 


The increasing investment in the Diabetic Nephropathy market by the leading players to improve the services has fueled the overall growth of the Diabetic Nephropathy market value. The increasing investments have significantly increased the R&D development for drug discovery, research works, and treatments for kidney-related disorders in recent years. These showed up significant performance in the global market in recent years. Additionally, these factors are expected to stimulate the growth of the Diabetic Nephropathy industry. 


Market restraints: 


Several countries have imposed stringent regulations over the drugs administrated for Diabetic Nephropathy. For instance, Captopril is the only drug among the other ACE inhibitors that have gotten FDA approval. Considering the interactions of the ACE inhibitors, the approval for them has always been difficult. This factor is considered as the primary restraint in the Diabetic Nephropathy market growth. 


The strict recommendation to avoid ACE inhibitors during pregnancy and lactation has restricted the growth of the Diabetic Nephropathy market value. The corresponding alternative that provides minimal drug reactions is expected by the market players. 


Market challenges: 


Lack of skilled professionals in the regions where the cases are surging is considered as the primary restraining factor of the Diabetic Nephropathy market growth. The emerging treatments that offer promising results are to be administered with the well-equipped and controlled method. Understanding the aspects associated with the novel drugs requires skilled professionals in Diabetic Nephropathy.  


The Oral administration of Spironolactone followed by Eplerenone has controlled the condition in a promising manner, however has created the risk of the development of hyperkalemia is suppressing. Since the combination of inhibitors is administrated in the treatments, the risks of renal failure are predominantly noticed when the ACE inhibitors are combined with ARBs. Adverse effects like diarrhea, hypotension, syncope, and hyperkalemia have been noted in such cases. These adverse effects of drugs have restricted the growth of the Diabetic Nephropathy industry. 


Cumulative growth analysis:


Diabetic Nephropathy treatment requires way more development. Incomplete therapeutic management and stringent regulations by the medical associations and federations have significantly hindered the growth of the Diabetic Nephropathy market growth in recent years. Additionally, despite series of research efforts, the market still lacks novel strategies and treatment to prevent or arrest the condition once encountered. In addition to that, the increasing fatality rates have imposed a significant effect on the growth of the Diabetic Nephropathy industry. 


Diabetic Nephropathy registering a CAGR of 5.2% during the forecast period. The new launches in the Diabetic Nephropathy market have created a significant impact on the growth. The understanding of the condition has increased tremendously in recent years and therefore personalized treatments and drugs are administrated to the patients which have shown a decent success rate. The improvement in renal and cardiovascular protection in diabetic patients has improved with intensive care and personalized prescription. However, the surging number of diabetic cases and increasing awareness regarding the condition has increased the Diabetic Nephropathy market growth.


Value chain analysis: 


Over 40% of patients with diabetes mellitus possess diabetic nephropathy where the kidney is constantly exposed to hyperglycemia. Diabetes has become common in several countries for the sedentary lifestyle, habits like alcohol consumption, improper diet, and genetics. There were over 26 million people in the United States who were reported diabetics, of which 200,000 patients were either on chronic renal dialysis or kidney transplant. These factors have impacted the growth of the Diabetic Nephropathy market across the globe. 


The major side effects of chronic diabetic nephropathy are progressive growth in proteinuria, renal failure, hypertension, higher risks of cardiovascular disease.  


Segment overview: 


Based on diagnosis: 



  • Blood test

  • Urine tests

  • Imaging tests

  • Renal function testing

  • Kidney biopsy 


Based on treatment:



  • Medications



  • Angiotensin-converting enzyme inhibitors angiotensin II receptor blockers

  • Antioxidant inflammation modulators, renin inhibitors

  • Diuretics

  • Calcium channel blockers

  • G- protein-coupled receptors,

  • Connective tissue growth factor inhibitors

  • Monocyte chemoattractant proteins inhibitor

  • Endothelin-A receptor antagonist



  • Kidney dialysis

  • Transplant 


Based on indication: 



  • Diabetes 1

  • Diabetes 2 


Regional analysis: 


The Diabetic Nephropathy market share of America is currently considered the largest among other countries in the world. Extensive use of diagnostic tests, continuous monitoring, and higher blood pressure rates in the patients are some of the major driving factors of the Diabetic Nephropathy market growth. Additionally, the other kidney-related complaints prevalently found in the region, over 15% of adults in the country is expected to have any one of the chronic kidney diseases which has also impacted the growth of the Diabetic Nephropathy industry in the United States. 


On the other hand, the European market is driven by diagnostic services and home diagnosis services. The emerging-market players in the manufacturers of medical devices have boosted the growth of the Diabetic Nephropathy industry in the region. Additionally, Asia-pacific is currently witnessing a higher number of cases related to chronic diseases like obesity, diabetes, cardiac arrests.  


Competitive landscape: 



  • Novartis AG, Merck & Co., Inc.

  • Pfizer, Inc.

  • Abbott Laboratories.

  • Sanofi.

  • Eli Lilly.

  • Company.

  • Reata Pharmaceuticals, Inc.

  • Bayer AG, AbbVie, Inc.

  • Mitsubishi Tanabe Pharma Corporation 


Recent developments: 


The administration of sodium-glucose cotransporter 2 inhibitors has been recently approved for treating Diabetic Nephropathy. The inhibitor has showcased positive effects on the kidney outcomes and reduction in albuminuria and progression of renal damage. 


Another recent approval from FDA to treat adults is Finerenone and Farxiga (brand name) in the year 2021. Dapagliflozin is very effective when administered to type 2 diabetic patients. The drug has significantly reduced the cardiovascular risk, and risk of kidney failure. The drug is found to be very effective when administered along with proper diet and exercise.  


Report overview: 


This report has covered: 



  • Market overview

  • COVID-19 Analysis

  • Market dynamics

  • Cumulative growth analysis

  • Value chain analysis

  • Segment overview

  • Regional analysis

  • Competitive landscape

  • Recent developments 


Segmentation Table: 


Based on diagnosis: 



  • Blood test

  • Urine tests

  • Imaging tests

  • Renal function testing

  • Kidney biopsy 


Based on treatment:



  • Medications



  • Angiotensin-converting enzyme inhibitors angiotensin II receptor blockers

  • Antioxidant inflammation modulators, renin inhibitors

  • Diuretics

  • Calcium channel blockers

  • G- protein-coupled receptors,

  • Connective tissue growth factor inhibitors

  • Monocyte chemoattractant proteins inhibitor

  • Endothelin-A receptor antagonist



  • Kidney dialysis

  • Transplant 


Based on indication: 



  • Diabetes 1

  • Diabetes 2



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   5.2% (2018-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment, Indication and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors    Merck & Co., Inc. (U.S.), Bayer AG (Germany), Abbott (U.S.), Sanofi (France), Novartis AG (Switzerland), Reata Pharmaceuticals, Inc. (U.S.), Pfizer Inc. (U.S.), AbbVie Inc. (U.S.), Eli Lilly and Company (U.S.), General Electric Company (U.S.), Siemens AG (Germany), Mitsubishi Tanabe Pharma Corporation (Japan)
  Key Market Opportunities   Technological advancements in diagnostic imaging
  Key Market Drivers

  • rising prevalence of chronic diseases diabetes, obesity
  • Increasing demand for diagnostic tests


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    Diabetic Nephropathy is a side effect of diabetes and is caused by the presence of high amounts of glucose in the blood, which makes the filters in the kidney porous and leaky.

    The market is expected to exhibit a strong 5.2% CAGR over the forecast period from 2017 to 2023.

    The growing prevalence of diabetes is the major driver for the market.

    The Americas dominated the global Diabetic Nephropathy Market in 2016.

    Leading players in the Diabetic Nephropathy Market include Merck, Bayer, and Abbott, among others.

    Table of Content


    1. Report Prologue

    2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    6. Global Diabetic Nephropathy Market, by Diagnosis

    6.1 Introduction

    6.2 Urine Test

    6.2.1 Market Estimates & Forecast, 2020-2027

    6.3 Blood Test

    6.3.1 Market Estimates & Forecast, 2020-2027

    6.4 Imaging tests

    6.4.1 Market Estimates & Forecast, 2020-2027


    6.5 Renal function testing

    6.5.1 Market Estimates & Forecast, 2020-2027

    6.6 Kidney biopsy

    6.6.1 Market Estimates & Forecast, 2020-2027

    7. Global Diabetic Nephropathy Market, by Treatment

    7.1 Introduction

    7.2 Medications

    7.2.1 Market Estimates & Forecast, 2020-2027

    7.3 Kidney Dialysis

    7.3.1 Market Estimates & Forecast, 2020-2027

    7.4 Transplant

    7.4.1 Market Estimates & Forecast, 2020-2027

    8. Global Diabetic Nephropathy Market, by Indication

    8.1 Introduction

    8.2 Diabetes 1

    8.2.1 Market Estimates & Forecast, 2020-2027

    8.3 Diabetes 2

    8.3.1 Market Estimates & Forecast, 2020-2027

    9. Global Diabetic Nephropathy Market, by End User

    9.1 Introduction

    9.2 Hospital & Clinics

    9.2.1 Market Estimates & Forecast, 2020-2027

    9.3 Surgical Centers

    9.3.1 Market Estimates & Forecast, 2020-2027

    10. Global Diabetic Nephropathy Market, by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 U.S.

    10.2.1.1 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 U.K

    10.3.1.4 Italy

    10.3.1.5 Spain

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic of Korea

    10.4.6 Rest of Asia Pacific

    10.5 The Middle East & Africa

    10.5.1 United Arab Emirates

    10.5.2 Saudi Arabia

    10.5.3 Oman

    10.5.4 Kuwait

    10.5.5 Qatar

    10.5.6 Rest of the Middle East & Africa

    11 Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    11.3.1 Key Developments

    12 Company Profiles

    12.1 Bayer AG

    12.1.1 Company Overview

    12.1.2 Product Overview

    12.1.3 Financials

    12.2 Merck & Co., Inc.

    12.2.1 Company Overview

    12.2.2 Product Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.3 Novartis AG

    12.3.1 Company Overview

    12.3.2 Product Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.4 Reata Pharmaceuticals, Inc.

    12.4.1 Company Overview

    12.4.2 Product/Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.5 Pfizer Inc.

    12.5.1 Company Overview

    12.5.2 Product Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.6 Abbott

    12.6.1 Company Overview

    12.6.2 Product Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.7 Sanofi

    12.7.1 Overview

    12.7.2 Product Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.8 Others

    13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Prediction of Healthcare Diagnostics Industry

    14 Appendix

    LIST OF TABLES

    Table 1 Diabetic Nephropathy Industry Synopsis, 2020-2027

    Table 2 Global Diabetic Nephropathy Market Estimates and Forecast, 2020-2027, (USD Million)

    Table 3 Global Diabetic Nephropathy Market by Region, 2020-2027, (USD Million)

    Table 4 Global Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)

    Table 5 Global Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)

    Table 6 Global Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)

    Table 7 Global Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)

    Table 8 North America Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)

    Table 9 North America Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)

    Table 10 North America Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)

    Table 11 North America Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)

    Table 12 US Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)

    Table 13 US Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)

    Table 14 US Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)

    Table 15 US Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)

    Table 16 Canada Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)

    Table 17 Canada Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)

    Table 18 Canada Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)

    Table 19 Canada Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)

    Table 20 South America Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)

    Table 21 South America Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)

    Table 22 South America Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)

    Table 23 South America Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)

    Table 24 Europe Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)

    Table 25 Europe Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)

    Table 26 Europe Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)

    Table 27 Europe Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)

    Table 28 Western Europe Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)

    Table 29 Western Europe Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)

    Table 30 Western Europe Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)

    Table 31 Western Europe Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)

    Table 32 Eastern Europe Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)

    Table 33 Eastern Europe Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)

    Table 34 Eastern Europe Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)

    Table 35 Eastern Europe Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)

    Table 36 Asia Pacific Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)

    Table 37 Asia Pacific Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)

    Table 38 Asia Pacific Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)

    Table 39 Asia Pacific Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)

    Table 40 Middle East & Africa Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)

    Table 41 Middle East & Africa Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)

    Table 42 Middle East & Africa Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)

    Table 43 Middle East & Africa Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Diabetic Nephropathy Market

    Figure 3 Segmentation Market Dynamics for Diabetic Nephropathy Market

    Figure 4 Global Diabetic Nephropathy Market Share, by Treatment 2020

    Figure 5 Global Diabetic Nephropathy Market Share, by Indication 2020

    Figure 6 Global Diabetic Nephropathy Market Share, by End Users, 2020

    Figure 7 Global Diabetic Nephropathy Market Share, by Region, 2020

    Figure 8 North America Diabetic Nephropathy Market Share, by Country, 2020

    Figure 9 Europe Diabetic Nephropathy Market Share, by Country, 2020

    Figure 10 Asia Pacific Diabetic Nephropathy Market Share, by Country, 2020

    Figure 11 Middle East & Africa Diabetic Nephropathy Market Share, by Country, 2020

    Figure 12 Global Diabetic Nephropathy Market: Company Share Analysis, 2020 (%)

    Figure 13 Bayer AG: Key Financials

    Figure 14 Bayer AG: Segmental Revenue

    Figure 16 Bayer AG: Geographical Revenue

    Figure 17 Merck & Co., Inc.: Key Financials

    Figure 18 Merck & Co., Inc.: Segmental Revenue

    Figure 19 Merck & Co., Inc.: Geographical Revenue

    Figure 20 Novartis AG: Key Financials

    Figure 21 Novartis AG: Segmental Revenue

    Figure 22 Novartis AG: Geographical Revenue

    Figure 23 Reata Pharmaceuticals, Inc.: Key Financials

    Figure 24 Reata Pharmaceuticals, Inc.: Segmental Revenue

    Figure 25 Reata Pharmaceuticals, Inc.: Geographical Revenue

    Figure 26 Abbott: Key Financials

    Figure 27 Abbott: Segmental Revenue

    Figure 28 Abbott: Geographical Revenue

    Figure 29 Pfizer Inc.: Key Financials

    Figure 30 Pfizer Inc.: Segmental Revenue

    Figure 31 Pfizer Inc.: Geographical Revenue

    Figure 32 Sanofi: Key Financials

    Figure 33 Sanofi: Segmental Revenue

    Figure 34 Sanofi: Geographical Revenue